GeneralConnection.com ➔ Dictionary
Dictionary Search

edgewise

Synonyms

Adverb

1. edgeways

2. edgeways

Usage
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PR Newswire
Edgewise data power rival to BMS and Cytokinetics toward phase 3 - Fierce Biotech
Edgewise stock yo-yos after Phase II data release for HCM candidate - FirstWord Pharma
Edgewise to advance heart drug into Phase 3 following mid-stage data update - Endpoints News
Edgewise reports positive top-line results from Phase II CIRRUS-HCM trial - Clinical Trials Arena
Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short - BioSpace
Biotech Whips Violently Between Red And Green — What's Going On? - Investor's Business Daily
Edgewise shares slip despite positive Phase II HCM data for EDG-7500 - The Pharma Letter
Edgewise Therapeutics (EWTX) director receives grant of 16,377 stock options - Stock Titan
Edgewise heads to phase III with solid EDG-7500 data in HCM - BioWorld News
Edgewise Edges Into Phase III With EDG-7500 - Citeline News & Insights
Goldman Sachs raises Edgewise Therapeutics stock price target on phase 2 data - Investing.com
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business - PR Newswire
Edgewise Therapeutics (EWTX) director granted 16,377 stock options at $35.59 - Stock Titan
Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline - Fierce Biotech
RBC Capital raises Edgewise Therapeutics price target on trial data - Investing.com
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - PR Newswire
[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity - Stock Titan
Edgewise Therapeutics (NASDAQ: EWTX) grants director equity awards - Stock Titan
Edgewise Therapeutics (EWTX) director receives grant of 16,377 stock options - Stock Titan
SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall - Investing.com
Truist reiterates Edgewise Therapeutics stock rating on phase 2 data - Investing.com
Edgewise Therapeutics Reports Improvements In Heart Drug Trial - Benzinga
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications - PR Newswire
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - Slideshow (NASDAQ:EWTX) 2026-06-17 - Seeking Alpha
Leerink reiterates Edgewise Therapeutics stock rating on trial data - Investing.com
How Positive CIRRUS-HCM Phase 2 Data and Preserved Systolic Function Will Impact Edgewise Therapeutics (EWTX) Investors - simplywall.st
US Premarket Movers for June 16, 2026 - Bloomberg.com
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn - Pharmaceutical Technology
Edgewise shares slip after heart-disease drug trial data disappoints investors - TradingView
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up - PR Newswire
Edgewise posts trial data for heart disease drug (EWTX:NASDAQ) - Seeking Alpha
Servier buys into muscular dystrophy with potentially $2.7B deal - BioPharma Dive
Edgewise reports phase 2 trial results for heart disease drug - Investing.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk - marketscreener.com
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal - Yahoo Finance
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics - MedCity News
Edgewise Therapeutics (EWTX) Shares Plunge 25% After Trial Update - GuruFocus
Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move - Yahoo Finance
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - PR Newswire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs - PR Newswire
Edgewise Therapeutics reports positive Phase 2 heart data - grafa.com
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers - PR Newswire
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 - PR Newswire
Edgewise Therapeutics Advances EDG-7500 to Phase 3 Following 'Positive' HCM Data - marketscreener.com
Edgewise shares slip after heart-disease drug trial data disappoints investors - marketscreener.com
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference - PR Newswire
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio - Pharmaceutical Executive
Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal - BioSpace
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - PR Newswire
Servier wagers $2.65bn on Edgewise muscular dystrophy drug - pharmaphorum
Edgewise Challenges Heart Disease Giants with Safer Drug Profile - BriefGlance
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 - PR Newswire
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - StreetInsider
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire
Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story? - Yahoo Finance
Edgewise Therapeutics stock tumbles 25% on trial data By Investing.com - Investing.com Nigeria
Edgewise falls after trial data for heart disease therapy - MSN
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang - Investor's Business Daily
Servier Agrees to Acquire Muscular Dystrophy Business of Edgewise Therapeutics - Contract Pharma
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn - European Biotechnology Magazine
Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline - Yahoo Finance
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors - PR Newswire
Edgewise sells muscular dystrophy assets to Servier for $2.65B - BioWorld News
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Edgewise Therapeutics (EWTX) shareholders approve directors, KPMG and executive pay - Stock Titan
Edgewise reports phase 2 trial results for heart disease drug By Investing.com - Investing.com South Africa
Leerink reiterates Edgewise Therapeutics stock rating on trial data By Investing.com - Investing.com India
Edgewise Therapeutics (EWTX) to sell sevasemten business to Servier for up to $2.65B - Stock Titan
A Word In Edgewise: All in the Family, Always - Lavender Magazine
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement - Seeking Alpha
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
New Edgewise hires get 74,000 stock options as hiring inducement - Stock Titan
David K. Lee: Servier Announces Acquisition of Edgewise Therapeutics’ Neuromuscular Business - Oncodaily
Edgewise sells sevasemten for up to $2.65 billion - The Pharma Letter
Edgewise falls after trial data for heart disease therapy - MSN
RBC Capital raises Edgewise Therapeutics price target on trial data By Investing.com - Investing.com Canada
Do New Analyst Upgrades and Option Grants Clarify Edgewise Therapeutics' (EWTX) Long-Term Story? - simplywall.st
Servier to spend up to $2.65B on Edgewise muscular dystrophy drugs - Stock Titan
Muscular dystrophy sale to bring Edgewise $1.55B for heart drugs - Stock Titan
Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi‑Year Returns And Recent Share Price Momentum - Yahoo Finance
Assessing Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term MESA Study Results - Yahoo Finance
Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference - Yahoo Finance
Edgewise reports phase 2 trial results for heart disease drug By Investing.com - Investing.com Canada
RBC Capital lowers Edgewise Therapeutics stock price target on deal - Investing.com
Why Edgewise Therapeutics (EWTX) Is Up 8.8% After Mapping Its 2026 Rare-Disease Pipeline Priorities – And What's Next - Yahoo Finance
Edgewise Therapeutics Inc (EWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire
Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026 - Yahoo Finance
Number of shareholders of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView
Why Edgewise Therapeutics Stock Topped the Market on Tuesday - The Motley Fool
Edgewise reports phase 2 trial results for heart disease drug By Investing.com - Investing.com UK
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Is Edgewise Therapeutics (EWTX) Stock Suitable for 2026 | Price at $32.50, Down 1.01% - Take Profit Levels - lwvtexas.org
Edgewise gives 4 new hires stock options for 72,000 shares - Stock Titan
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society - PR Newswire
Raymond James raises Edgewise Therapeutics price target on Servier deal - Investing.com
Edgewise Therapeutics Teases Phase 3 Sevasemten Readout, HCM Data Update at Guggenheim Conference - Yahoo Finance
Foreign Language Equivalents
Foreign Language Equivalents of 'edgewise'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
edgewsie,   egewise,   edgwwise,   edgewide,   edgewisee,   eddgewise,   edgwise,   edgeewise,   edgeeise,   edgweise,   rdgewise,   edhewise,   edgewiise,   edgewse,   edgewisr,   edgrwise,   edegwise,   edgewose,   dgewise,   edgewis,   wdgewise,   edgewie,   edgewisse,   efgewise,   edgewuse,   esgewise,   eedgewise,   edgeqise,   edgewies,   edgewisw,   edewise,   egdewise,   edfewise,   degewise,   edggewise,   edgewiae,   edgeiwse,   edgeise,   edgewwise
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z